Disclosed is a combination therapy for cancer. Additionally, the administration of inhibitors of the phosphoinositide 3-kinase (PI3K) signaling pathway and the Wnt signaling pathway are disclosed for treatment of cancer, and in particular, triple-negative breast cancer (TNBC).